Leerink Partnrs Has Bearish Forecast for Hologic Q2 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Stock analysts at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for Hologic in a research report issued on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical equipment provider will post earnings per share of $1.02 for the quarter, down from their prior estimate of $1.03. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. Leerink Partnrs also issued estimates for Hologic’s Q2 2026 earnings at $1.15 EPS, Q3 2026 earnings at $1.18 EPS, Q4 2026 earnings at $1.19 EPS and FY2026 earnings at $4.65 EPS.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million during the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter last year, the business earned $0.89 earnings per share. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year.

Several other equities analysts have also recently issued reports on HOLX. Mizuho reduced their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. Evercore ISI lifted their price target on Hologic from $78.00 to $82.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. UBS Group boosted their price objective on shares of Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Citigroup downgraded shares of Hologic from a “buy” rating to a “neutral” rating and dropped their target price for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. Finally, StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a report on Thursday, November 14th. Seven equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Hologic presently has an average rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Price Performance

HOLX stock opened at $71.19 on Wednesday. The firm has a 50 day moving average of $74.30 and a 200-day moving average of $78.31. The company has a market cap of $16.07 billion, a price-to-earnings ratio of 21.38, a PEG ratio of 2.38 and a beta of 0.97. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. Hologic has a 12-month low of $68.61 and a 12-month high of $84.67.

Institutional Investors Weigh In On Hologic

Hedge funds have recently modified their holdings of the stock. Wolff Wiese Magana LLC purchased a new position in Hologic during the third quarter worth approximately $25,000. General Partner Inc. purchased a new stake in Hologic during the fourth quarter valued at about $26,000. First Horizon Advisors Inc. increased its stake in Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Sunbelt Securities Inc. purchased a new position in shares of Hologic in the 2nd quarter worth about $37,000. Finally, Cromwell Holdings LLC lifted its stake in shares of Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock valued at $44,000 after purchasing an additional 416 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of Hologic stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at $2,134,237.38. The trade was a 47.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 1.88% of the company’s stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.